Humans are essentially sterile until birth. At birth, every body surface, including the skin, mouth and gut become host to an enormous variety of bacteria. As they develop and grow, babies pick up bacteria from their mothers and every person and thing that they touch. This means that babies who are born at home are exposed to different bacteria than babies born in a hospital. These differences are still measurable months and even years after birth.
Under normal circumstances, the bacteria play an important role in maintaining our health, helping us digest our food and regulate our immune system. The highest concentration of microbes in the body live in the gut, where there are over a trillion different microbes from over 500 different species. The scientific term for the ecosystem of microbes that live within the gut is ‘microbiota’, and the scientific term for the microbiota and their genes is ‘microbiome’.
Often referred to as our “forgotten organ“, the microbiome represents a new, and still to be fully explored, exciting frontier in human health and medicine. Imbalances in gut microbiome composition and function, termed ‘dysbiosis’, is associated with several illnesses such as Clostridium difficile (C.diff) infection as well as gastrointestinal and autoimmune diseases including Inflammatory Bowel Disease.
There is at present, no simple or effective way to restore the bacterial balance in these illnesses. Medical therapies such as probiotics rarely improve gut bacterial diversity. An alternative strategy called Faecal Microbiota Transplantation (FMT) offers a promising alternative to probiotics as it delivers a greater variety of bacteria from a stool sample. FMT is now accepted as standard care for antibiotic resistant C.diff infection. However, FMT is currently manufactured using non-standardised processes and is administered by invasive medical procedures such as colonoscopy
We have established a state-of-the-art cleanroom manufacturing facility situated on the central site of one the largest medical campus in Europe. We’re using this platform to manufacture allogenic (from a donor) and autologous (using a person’s own bacteria) microbial therapeutics for using standardised, quality controlled and quantifiable processes.
EnteroBiotix is developing and validating a proprietary microbe delivery system (MicrobeDS) that enables site-specific delivery, patient-friendly administration and increased product shelf-life. MicrobeDS removes the need for the invasive medical procedures currently used to administer FMT and will also have the added benefit of simplifying the design of placebo-controlled clinical trials.
The majority of the human gut microbiota is composed of anaerobic bacteria. Reductions in anaerobic bacteria have been observed in patients suffering from diseases such as Inflammatory Bowel Disease. Current methods of manufacture involve open systems in aerobic environments, which likely compromise the viability of therapeutically active anaerobic bacteria. To address this, we are developing a closed system collection and processing benchtop system that will allow therapies to be produced outside of cleanrooms and in anaerobic environments.
Imbalances of the bacteria that live within our gut occur as a result of long courses of chemotherapy or antibiotics. There is at present, no simple or effective way to restore the bacterial balance following such treatments. Autologous FMT (aFMT), where a patient banks their own microbiota for reinstatement after medical therapy, offers a promising alternative to probiotics. However, aFMT is not currently available to patients and is administered by invasive medical procedures. We are seeking to solve these problems by producing an encapsulated aFMT product that remains effective at room temperature. This platform will be the first of its kind and has the potential to create cost savings in the NHS and benefit all patients undergoing intensive chemotherapy or antibiotics.
We are seeking to solve these problems by producing encapsulated aFMT products that remain stable and effective at room temperature. This platform will be the first of its kind and has the potential to create significant cost savings in healthcare systems.
We’re a multi-award winning biotechnology company that was formed to support doctors treat a wide range of diseases by tapping into the power of the bacterial populations flourishing inside the human gut. We are strategically located in the heart of the University of Aberdeen’s health science complex, one of the largest healthcare campuses in Europe. We have a committed and talented team that is developing and commercialising a pipeline of products designed to treat the gut using the microbiome and its derivatives as a new treatment modality in healthcare. To support our scientific and commercial development, we have appointed a world class independent Scientific and Medical Advisory Board and forged high profile research collaborations with leading academic institutions.
|Colin Bennett||Non-Executive Chairman|
|Dr James Clark||Non-Executive Director|
|Gavin Clark||Non-Executive Director|
|Andrew Coleman||Investor Director|
|Professor Sir Lewis Ritchie||Non-Executive Director|